Abstract 344P
Background
Acute myeloid leukemia (AML) is primarily treated with chemotherapy. Patients who are unable to undergo intensive chemotherapy may receive substitutional therapy, such as venetoclax, a BCL-2 inhibitor that showed promising results by combining it with azacitidine. Recent clinical trials have demonstrated the effectiveness of venetoclax-azacitidine in AML treatment. Thus, this review aims to compare the efficacy and serious adverse events (SAE) of venetoclax-azacitidine vs azacitidine used alone in patients diagnosed with AML.
Methods
Authors independently extracted studies from 2013 to 2023 using databases such as Pubmed, Pubmed Central, Springer Link, ScienceDirect, Medrxiv, and Google Scholar. Keywords used were "venetoclax" AND "azacitidine" AND "acute myeloid leukemia". We assessed the quality of each study using the modified JADAD scale with funnel plot to assess publication bias and Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) to determine the quality of this review. A pooled analysis of OS and EFS hazard ratio (HR) and SAE ratio between the two groups were done to establish correlation.
Results
We included 7 records, representing 3 trials, involving 1499 patients. 2 studies were of low quality, with the other 3 studies and the other 2 studies were of moderate and high quality respectively. This review showed moderate quality based on GRADE with minimum publication bias. The use of combining venetoclax and azacitidine did improve OS (HR = 0.58; 95% CI 0.51-0.65 ; P < 0.001) and EFS (HR = 0.50 ; 95% CI 0.30-0.84 ; P = 0.008), but have higher SAE (OR = 1.81 ; 95% CI 1.29-2.52 ; P = 0.0005) compared to azacitidine alone.
Conclusions
This review revealed that venetoclax-azacitidine demonstrated enhanced OS and EFS outcomes, with higher serious adverse events (SAE) when compared to azacitidine in AML patients. This concludes that venetoclax-azacitidine holds promise as a potential treatment for AML patients although its safety still needs to be monitored closely. Further studies needed to observe the administration of venetoclax-azacitidine vs azacitidine AML in different subgroups, more importantly the cytogenetic risk.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
426P - Characterization of a novel comprehensive genomic profiling test with better detection of heterozygous deletions and gene fusions
Presenter: ryouta kakuta
Session: Poster Display
Resources:
Abstract
427P - Real-world performance of a comprehensive next-generation sequencing (NGS) panel for patients (pts) with solid tumors from Asia and the Middle East (AME)
Presenter: Nitesh Rohatgi
Session: Poster Display
Resources:
Abstract
428P - What do women want to see in a personalized breast cancer risk report? A qualitative study of Asian women of two countries
Presenter: Faustina Audrey Agatha
Session: Poster Display
Resources:
Abstract
429P - Clinical utility and outcomes of liquid biopsy-based next generation sequencing in identification of actionable genomic mutations in solid malignancy: A single center retrospective study in the Philippines
Presenter: Omar Maaño
Session: Poster Display
Resources:
Abstract
436P - Chemotherapy-induced hand-foot syndrome, comparative efficacy and safety of pharmacological prophylaxis: Systematic review and network meta-analysis
Presenter: Anand Srinivasan
Session: Poster Display
Resources:
Abstract
437P - A randomized single blinded phase II trial comparing efficacy and quality of life of topical aloe vera gel plus urea cream versus urea cream alone for prevention of hand-foot syndrome in cancer patients receiving capecitabine
Presenter: Lucksika Wanichtanom
Session: Poster Display
Resources:
Abstract
438P - A novel treatment for immune checkpoint inhibitor-related myocarditis
Presenter: Takahiro Niimura
Session: Poster Display
Resources:
Abstract
439P - Randomized controlled trial evaluating efficacy of topical urea-based cream for capecitabine-associated hand-foot syndrome prevention
Presenter: Concord Wongkraisri
Session: Poster Display
Resources:
Abstract
440P - Real-world adverse events of targeted therapy reported by pharmacist in oncology clinic
Presenter: TIKUMPORN PORNWISETSIRIKUL
Session: Poster Display
Resources:
Abstract
441P - The prophylactic efficacy of telpegfilgrastim, a Y-shape branched pegylated G-CSF in patient with chemotherapy-induced neutropenia: A multicenter, randomized phase III study
Presenter: Xinshuai Wang
Session: Poster Display
Resources:
Abstract